The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Treatment of Obese Diabetic Mice With a Heme Oxygenase Inducer Reduces Visceral and Subcutaneous Adiposity, Increases Adiponectin Levels, and Improves Insulin Sensitivity and Glucose Tolerance
Abstract
OBJECTIVE—We hypothesized that the induction of heme oxygenase (HO)-1 and increased HO activity, which induces arterial antioxidative enzymes and vasoprotection in a mouse and a rat model of diabetes, would ameliorate insulin resistance, obesity, and diabetes in the ob mouse model of type 2 diabetes. RESEARCH DESIGN AND METHODS—Lean and ob mice were intraperitoneally administered the HO-1 inducer cobalt protoporphyrin (3 mg/kg CoPP) with and without the HO inhibitor stannous mesoporphyrin (2 mg/100 g SnMP) once a week for 6 weeks. Body weight, blood glucose, and serum cytokines and adiponectin were measured. Aorta, adipose tissue, bone marrow, and mesenchymal stem cells (MSCs) were isolated and assessed for HO expression and adipogenesis. RESULTS—HO activity was reduced in ob mice compared with age-matched lean mice. Administration of CoPP caused a sustained increase in HO-1 protein, prevented weight gain, decreased visceral and subcutaneous fat content (P < 0.03 and 0.01, respectively, compared with vehicle animals), increased serum adiponectin, and decreased plasma tumor necrosis factor-α (TNF-α), interleukin (IL)-6, and IL-1β levels (P < 0.05). HO-1 induction improved insulin sensitivity and glucose tolerance and decreased insulin levels. Upregulation of HO-1 decreased adipogenesis in bone marrow in vivo and in cultured MSCs and increased adiponectin levels in the culture media. Inhibition of HO activity decreased adiponectin and increased secretion of TNF-α, IL-6, and IL-1β levels in ob mice. CONCLUSIONS—This study provides strong evidence for the existence of an HO-1–adiponectin regulatory axis that can be manipulated to ameliorate the deleterious effects of obesity and the metabolic syndrome associated with cardiovascular disease and diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity
Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J.-I., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0255 · Cited by 4,856
Inflammation, stress, and diabetes
Wellen, K. E., & Hotamisligil, G. S. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25102 · Cited by 4,143
Weyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Pratley, R. E., & Tataranni, P. A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7463 · Cited by 3,541
The adipocyte-secreted protein Acrp30 enhances hepatic insulin action
Berg, A. H., Combs, T. P., Du, X., Brownlee, M., & Scherer, P. E. (2001) · Nature Medicine · doi:10.1038/90992 · Cited by 2,526
Adipose Tissue, Inflammation, and Cardiovascular Disease
Berg, A. H., & Scherer, P. E. (2005) · Circulation Research · doi:10.1161/01.res.0000163635.62927.34 · Cited by 2,113
Kern, P. A., Ranganathan, S., Li, C., Wood, L., & Ranganathan, G. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.5.e745 · Cited by 1,883
Visceral fat adipokine secretion is associated with systemic inflammation in obese humans
Fontana, L., Eagon, J. C., Trujillo, M. E., Scherer, P. E., & Klein, S. (2007) · Diabetes · doi:10.2337/db06-1656 · Cited by 1,417 · cited 1×
“The latter is an indicator of improvements in the metabolic syndrome which, in turn, leads to decreases in arterial diseases, heart disease and increased insulin sensitivity (3,10,37,39-41).”
BackgroundYamauchi, T., Nio, Y., Maki, T., Kobayashi, M., Takazawa, T., Iwabu, M., Okada-Iwabu, M., Kawamoto, S., Kubota, N., Kubota, T., et al. (2007) · Nature Medicine · doi:10.1038/nm1557 · Cited by 1,396
Obesity-associated improvements in metabolic profile through expansion of adipose tissue
Kim, J.-Y., van de Wall, E., Laplante, M., Azzara, A., Trujillo, M. E., Hofmann, S. M., Schraw, T., Durand, J. L., Li, H., Li, G., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31021 · Cited by 1,310 · cited 5×
“While increases in obesity are considered a risk factor for cardiovascular complications (37), obesityassociated improvement in the diabetic phenotype, including increases in insulin sensitivity and glucose tolerance, may occur through adipose tissue and increased adiponectin secretion (10,42).”
BackgroundResultInfluentialPharmacological and Clinical Aspects of Heme Oxygenase
Abraham, N. G., & Kappas, A. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07104 · Cited by 1,115
Self-citation
Cited by
Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction
Achari, A., & Jain, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061321 · Cited by 1,158
Pharmacological and Clinical Aspects of Heme Oxygenase
Abraham, N. G., & Kappas, A. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07104 · Cited by 1,115
Self-citationSivitz, W. I., & Yorek, M. A. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2531 · Cited by 742
Foundations of Immunometabolism and Implications for Metabolic Health and Disease
Hotamisligil, G. S. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.009 · Cited by 505
Role of free fatty acids in endothelial dysfunction
Ghosh, A., Gao, L., Thakur, A., Siu, P. M., & Lai, C. W. K. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0357-5 · Cited by 414
The Role of Bilirubin in Diabetes, Metabolic Syndrome, and Cardiovascular Diseases
Vítek, L. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00055 · Cited by 311
Adiponectin and cardiovascular health: an update
Hui, X., Lam, K. S., Vanhoutte, P. M., & Xu, A. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01395.x · Cited by 286
Heme Oxygenase-1 Drives Metaflammation and Insulin Resistance in Mouse and Man
Jais, A., Einwallner, E., Sharif, O., Gossens, K., Lu, T. T.-H., Soyal, S. M., Medgyesi, D., Neureiter, D., Paier-Pourani, J., Dalgaard, K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.04.043 · Cited by 269
Heme oxygenase-1: from biology to therapeutic potential
Soares, M. P., & Bach, F. H. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.12.004 · Cited by 257
Activating Transcription Factor 3 and the Nervous System
Hunt, D., Raivich, G., & Anderson, P. N. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00007 · Cited by 162
The Bone Marrow-Derived Stromal Cells: Commitment and Regulation of Adipogenesis
Tencerova, M., & Kassem, M. (2016) · Frontiers in Endocrinology · doi:10.3389/fendo.2016.00127 · Cited by 149
Cao, J., Peterson, S. J., Sodhi, K., Vanella, L., Barbagallo, I., Rodella, L. F., Schwartzman, M. L., Abraham, N. G., & Kappas, A. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.193805 · Cited by 94
Self-citationKim, Y., Kim, C.-S., Joe, Y., Chung, H. T., Ha, T. Y., & Yu, R. (2018) · Journal of Medicinal Food · doi:10.1089/jmf.2017.4108 · Cited by 69
Issan, Y., Kornowski, R., Aravot, D., Shainberg, A., Laniado-Schwartzman, M., Sodhi, K., Abraham, N. G., & Hochhauser, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092246 · Cited by 68
Self-citationNdisang, J. F., & Jadhav, A. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.91000.2008 · Cited by 46
Metadata
- Authors
- Li, M., Kim, D. H., Tsenovoy, P. L., Peterson, S. J., Rezzani, R., Rodella, L. F., Aronow, W. S., Ikehara, S., & Abraham, N. G.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2008-06-01
- Volume
- 57
- Issue
- 6
- Pages
- 1526-1535
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2171480976
- Cited by
- 311
- References
- 53
- FWCI
- 9.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.